"Diffuse large B cell lymphoma" trang 1 - tải miễn phí từ tailieunhanh
Clinical significance of BCL2, C-MYC, and BCL6 genetic abnormalities, epstein barr virus infection, CD5 protein expression, germinal center B cell non germinal center B cell subtypes, Co-expression of MYC/BCL2 proteins and Co-expression of MYC/BCL2/BCL6 proteins in diffuse large B-cell lymphoma: A clinical and pathological correlation study of 120 patients

Clinical significance of BCL2, C-MYC, and BCL6 genetic abnormalities, epstein barr virus infection, CD5 protein expression, germinal center B cell non germinal center B cell subtypes, Co-expression of MYC/BCL2 proteins and Co-expression of MYC/BCL2/BCL6 proteins in diffuse large B-cell lymphoma: A clinical and pathological correlation study of 120 patients
11    110    0
Diffuse large B cell lymphoma derived from nodular lymphocyte predominant Hodgkin lymphoma presents with variable histopathology

Diffuse large B cell lymphoma derived from nodular lymphocyte predominant Hodgkin lymphoma presents with variable histopathology
10    56    1
P38 MAPK expression and activation predicts failure of response to CHOP in patients with Diffuse Large B-Cell Lymphoma

P38 MAPK expression and activation predicts failure of response to CHOP in patients with Diffuse Large B-Cell Lymphoma
12    68    1
Clinical and prognostic features of non hodgkin lymphoma and preliminary effective evaluation of R-chop regimen in patients with diffuse large B-cell lymphoma

Clinical and prognostic features of non hodgkin lymphoma and preliminary effective evaluation of R-chop regimen in patients with diffuse large B-cell lymphoma
8    65    1
Establishment of a typing model for diffuse large B-cell lymphoma based on B-cell receptor repertoire sequencing

Establishment of a typing model for diffuse large B-cell lymphoma based on B-cell receptor repertoire sequencing
10    50    1
Prognostic model based on the geriatric nutritional risk index and sarcopenia in patients with diffuse large B-cell lymphoma

Prognostic model based on the geriatric nutritional risk index and sarcopenia in patients with diffuse large B-cell lymphoma
10    66    0
Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms

Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms
11    59    1
Increased risk of gastric adenocarcinoma after treatment of primary gastric diffuse large B-cell lymphoma

Increased risk of gastric adenocarcinoma after treatment of primary gastric diffuse large B-cell lymphoma
6    72    1
Treatment strategies and prognostic factors of primary gastric diffuse large B cell lymphoma: A retrospective multicenter study of 272 cases from the China lymphoma patient registry

Treatment strategies and prognostic factors of primary gastric diffuse large B cell lymphoma: A retrospective multicenter study of 272 cases from the China lymphoma patient registry
9    98    0
Prognostic significance of serum aspartic transaminase in diffuse large B-cell lymphoma

Prognostic significance of serum aspartic transaminase in diffuse large B-cell lymphoma
9    100    0
MYC and BCL2 overexpression is associated with a higher class of Memorial SloanKettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system

MYC and BCL2 overexpression is associated with a higher class of Memorial SloanKettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system
11    93    1
Histone regulator KAT2A acts as a potential biomarker related to tumor microenvironment and prognosis of diffuse large B cell lymphoma

Histone regulator KAT2A acts as a potential biomarker related to tumor microenvironment and prognosis of diffuse large B cell lymphoma
15    6    1
Dissemination feature based on PET/CT is a risk factor for diffuse large B cell lymphoma patients outcome

Dissemination feature based on PET/CT is a risk factor for diffuse large B cell lymphoma patients outcome
11    4    1
Primary diffuse large B-cell lymphoma of the prostate: A case report and review of the literature

Primary diffuse large B-cell lymphoma of the prostate: A case report and review of the literature
5    19    1
Red blood cell distribution width and platelet counts are independent prognostic factors and improve the predictive ability of IPI score in diffuse large B-cell lymphoma patients

Red blood cell distribution width and platelet counts are independent prognostic factors and improve the predictive ability of IPI score in diffuse large B-cell lymphoma patients
11    80    0
Enhancement of the International prognostic index with β2-microglobulin, platelet count and red blood cell distribution width: A new prognostic model for diffuse large B-cell lymphoma in the rituximab era

Enhancement of the International prognostic index with β2-microglobulin, platelet count and red blood cell distribution width: A new prognostic model for diffuse large B-cell lymphoma in the rituximab era
14    44    1
CDC6, a key replication licensing factor, is overexpressed and confers poor prognosis in diffuse large B-cell lymphoma

CDC6, a key replication licensing factor, is overexpressed and confers poor prognosis in diffuse large B-cell lymphoma
11    5    1
A study of pathological characteristics of pediatric non-Hodgkin lymphoma based on 2008 version of the world health organization classification of lymphoid neoplasms at children’s hospital 1

A study of pathological characteristics of pediatric non-Hodgkin lymphoma based on 2008 version of the world health organization classification of lymphoid neoplasms at children’s hospital 1
7    97    0
Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: A population-based analysis

Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: A population-based analysis
11    47    1
Prognostic significance of pretreatment serum free fatty acid in patients with diffuse large B-cell lymphoma in the rituximab era: A retrospective analysis

Prognostic significance of pretreatment serum free fatty acid in patients with diffuse large B-cell lymphoma in the rituximab era: A retrospective analysis
9    61    1